Emyria Ltd (emd) Logo

Emyria Ltd (EMD)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

EMD Chart

EMD's Principal Activity is the provide care for its patients through Emeralds specialist clinics whilst gathering Real-World-Evidence (RWE) insights in relation to novel therapies such as medicinal cannabinoid.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +224.44%
vs ASX 200 (1yr) +187.05%

Size

Market Capitalisation
ASX Rank 1686 of 2,564
Sector Rank 145 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies ATX / AZV / UCM
EPS -$0.01
DPS $0.00
NTA per share $0.02

Broker Consensus

EMD is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Emyria Limited (EMD, formerly Emerald Clinics Limited) operates a Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology to gather high quality clinical data from informed and consenting patients. EMD's model provides a clinical services and healthcare technology that focused on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office North Perth WA 6006
Website www.emyria.com
Registry Automic Group
Auditor Stantons International Audit and Consulting Pty Ltd
Date Listed 12 Feb 2020

Upcoming Calendar

Date Event
30/08/2021 Report (Prelim)
08/10/2021 Report (Annual)
23/02/2022 Report (Interim)

Dividend History

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Sir John Tooke Non-Executive Director Feb 2020 Director Bio icon

Sir John Tooke

Non-Executive Director

Sir Tooke is Executive Chairman of Academic Health Solutions, a start-up Group offering advice to clients internationally on medical research and health service transformation. He is Senior Independent Director at BUPA Chile and was until 2019 non-executive director of the BUPA main Board and the Chair of the Medical Advisory Council. He is the Chair of Collaboration for the Advancement of Medical Innovation (CASMI) UCL and Chaired the Oversight Group for the Academy of Medical Sciences project. He also served as an Review Board Member for Google Health (UK). Sir Tooke was Head of the School of Life and Medical Sciences at University College London (UCL) as Vice Provost (Health) and Academic Director of UCL Partners from 2010 - 2015. He is the Past President of the Academy of Medical Sciences in the UK. Sir Tooke has 30 years experience as a consultant physician specialising in diabetes, endocrinology, vascular medicine and internal medicine with research experience (basic biomedical, medicine, and health research and also includes improvement science) recognised through Fellowship of the Academy of Medical Sciences. He held a Board position at the Francis Crick Institute (2011 - 2015) and was a Member of the Council for Science & Technology (2011-2015) reporting to the Prime Minister (UK).

Dr Michael Winlo Managing Director Nov 2019 Director Bio icon

Dr Michael Winlo

Managing Director

Dr Winlo was CEO at Linear Clinical Research Ltd (Linear) until October 2019, a company that provides clinical trial services for US and Asia-based biotech companies. Linear adopt electronic data capture technology. Dr Winlo retains a Directorship at Linear. Prior to Linear, He was Health Lead at Palantir Technologies, a Big Data company based in Silicon Valley California.

Dr Alistair Vickery Executive Director Nov 2018 Director Bio icon

Dr Alistair Vickery

Executive Director

Dr Vickery has expertise in clinical practice, health service management, clinical and educational research and board director skills. He is adjunct Clinical Professor of Primary Health Care at the University of Western Australia and Notre Dame University. He is the clinical lead of the research group CHASM (The Collaborative for Health Care Analysis and Statistical Modelling) which provides analysis modelling to inform clinical service planning and service evaluation. He is Board Chair of Black Swan Health, one of NFP health care service providers in Western Australia.

Mr Matthew (Matt) Callahan Non-Executive Director Mar 2018 Director Bio icon

Mr Matthew (Matt) Callahan

Non-Executive Director

Mr Callahan is a life sciences executive with experience. He has been the founder, CEO or Executive Director of a number of pharmaceutical and health tech companies which includes Churchill Pharma Inc. He has led the development of four pharmaceutical products that have received FDA approval and he has more than 25 years legal, IP and investment management experience. Mr Callahan has worked as an investment director for two venture capital firms investing in lifesciences, technology and other sectors.

Dr Stewart James Washer Executive Chairman,Executive Director Mar 2018 Director Bio icon

Dr Stewart James Washer

Executive Chairman,Executive Director

Dr Washer has 25 years of CEO and Board experience in medical and agrifood biotech companies. Dr Washer has held a number of Board positions in the past which include Chairman of Hatchtech Pty Ltd and was a Director of iCeutica that was sold to a US Pharma. He was also a Senator with Murdoch University and was a Director of AusBiotech Ltd. Dr Washer was previously Chairman of Minomic International Ltd cancer diagnosis and treatment.

Mr Simon Lee Robertson Company Secretary N/A
Su-Mei Sain Chief Financial Officer N/A
Adam James Chief Operating Officer N/A

Director Transactions

EMD directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
13/11/20 John Tooke Issued 1,000,000 $0.076 $76,000 Issue of options
13/11/20 Matthew (Matt) Callahan Issued 1,500,000 $0.076 $114,000 Issue of options
13/11/20 Alistair Vickery Issued 2,000,000 $0.076 $152,000 Issue of options
13/11/20 Michael Winlo Issued 4,000,000 $0.076 $304,000 Issue of options
12/11/20 Stewart Washer Buy +255,000 $0.08 $20,321 On-market trade
11/11/20 Stewart Washer Buy +150,000 $0.082 $12,283 On-market trade
10/11/20 Stewart Washer Buy +100,000 $0.08 $7,986 On-market trade
09/11/20 Stewart Washer Buy +270,000 $0.077 $20,765 On-market trade
19/10/20 Alistair Vickery Buy +128,000 $0.078 $10,002 On-market trade
16/03/20 Stewart Washer Buy +100,000 $0.061 $6,110 On-market trade
16/03/20 Stewart Washer Buy +100,000 $0.061 $6,110 On-market trade
10/03/20 Stewart Washer Buy +58,500 $0.09 $5,290 On-market trade
09/03/20 Stewart Washer Buy +120,500 $0.089 $10,668 On-market trade
06/03/20 Stewart Washer Buy +271,499 $0.089 $24,182 On-market trade
06/03/20 Stewart Washer Buy +271,499 $0.089 $24,182 On-market trade

Director Interests

The current holdings of EMD directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Alistair Vickery 13/11/2020 N/A 128,000 4,000,000 N/A
Michael Winlo 13/11/2020 N/A N/A 7,500,000 N/A
John Tooke 13/11/2020 N/A N/A 1,500,000 N/A
Matthew (Matt) Callahan 13/11/2020 N/A 19,600,000 1,500,000 N/A
Stewart Washer 12/11/2020 N/A 49,325,599 1,500,000 N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Oct 6, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Stewart James Washer & Patrizia Derna Washer <The Washer Family A/C> 28,400,000 13.43%
Mal Washer Nominees Pty Ltd <Mal Washer Family No1 A/C> 19,600,000 9.27%
Mercator Shipwrights Pty Ltd <Mecator A/C> 19,600,000 9.27%
Mr Craig Lawrence Darby <Craig Lawrence Darby A/C> 19,600,000 9.27%
Lakevvest Pty Ltd <Raymond Desmond Family A/C> 5,160,532 2.44%
Mr Stephen Peter Somerville 4,900,000 2.32%
Mr Pak Lim Kong 3,416,667 1.62%
National Nominees Limited 2,600,000 1.23%
Mr Andrew Warren Simmons & Mrs Peta Sarah Lloyd Harris <Andeta Family A/C> 2,513,431 1.19%
Mr Craig Lawrence Darby 2,000,000 0.95%
Alexander Holdings (Wa) Pty Ltd 2,000,000 0.95%
Pac Partners Securities Pty Ltd 1,990,000 0.94%
D Schecter Medicine Professional Corporation 1,960,000 0.93%
Adam James <Araucariaa/C> 1,960,000 0.93%
Hsbc Custody Nominees (Australia) Limited 1,828,167 0.86%
Cann Group Limited 1,562,500 0.74%
Canopy Growth Corporation 1,562,500 0.74%
Baza High Conviction Pty Ltd <Baza High Conviction A/C> 1,398,431 0.66%
Mr Pak Lim Kong (I) 1,250,027 0.59%
Liddle Investments Group Pty Ltd <Liddle Super Fund A/C> 1,250,000 0.59%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 7 23 187 374 221 812

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Craig Lawrence Darby 07/09/2020 22,709,790 10.74
Mercator Shipwrights Pty Ltd 07/09/2020 19,600,000 9.27
Mal Washer Nominees Pty Ltd 07/09/2020 19,600,000 9.27
Stewart James Washer 22/12/2020 49,325,599 21.87

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
22-12-20 Stewart James Washer 775,100 22.90 21.87
07-09-20 Stewart James Washer 550,499 26.10 22.90
07-09-20 Craig Lawrence Darby 884,790 11.87 10.74

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.048 30 June
Page Icon
EMD Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.